“Suspicionless marijuana testing never has been an evidence-based policy. Rather, these discriminatory practices are a holdover from the zeitgeist of the 1980s ‘war on drugs.’ But times have changed; attitudes have changed, and in many places, the marijuana laws have changed. It is time for workplace policies to adapt to this new reality.”
The proposed measure expands the discretion of physicians so that they can recommend cannabis therapy for “any condition” that he or she “considers debilitating to an individual patient and is qualified through his [or her] medical education and training to treat.”
A study headed by Elizabeth O’Connor, PhD, at the Kaiser Permanente Evidence-based Practice Center in Portland, Oregon, has bad news for drug counselors and the youth-focused drug prevention industry:
26-MAY-2020–Bottom Line: The U.S. Preventive Services Task Force (USPSTF) has concluded that current evidence is insufficient to make a recommendation regarding primary care-based behavioral counseling […]
“This feasibility trial demonstrated that a metered-dose cannabis inhaler delivered precise and low THC doses [that] produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/complex-regional pain syndrome.”
In his veto message, the Governor wrote: “The language in the bill makes substantial policy changes to the medical marijuana program that were not fully scrutinized through normal legislative procedures before the bill was received by my office in the middle of the night Saturday. While there is much room for improvement in the way our state’s program operates, this bill does not address those items in a way I can support.”
Hugh Hefner and the Playboy Foundation ended up providing NORML’s initial funding in early 1971 and subsequently became our primary funder throughout the 1970s.